Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ocugen Inc (NQ: OCGN )

0.8531 +0.0296 (+3.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,125,536
Open 0.8374
Bid (Size) 0.8500 (3)
Ask (Size) 0.8550 (41)
Prev. Close 0.8235
Today's Range 0.8200 - 0.8687
52wk Range 0.8200 - 3.480
Shares Outstanding 198,755,831
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress
From Ocugen
Via Globe NewsWire
Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
From Ocugen
Via Globe NewsWire

Performance

YTD
-31.75%
-31.75%
1 Month
-14.66%
-14.66%
3 Month
-31.75%
-31.75%
6 Month
-52.07%
-52.07%
1 Year
-74.15%
-74.15%

More News

Read More
Ocugen, Inc. to Participate in Fireside Chat at 35th Annual Roth Conference
From Ocugen
Via Globe NewsWire
Why Ocugen Stock Eked Out a Win Today
Via The Motley Fool
Ocugen (OCGN) Q4 2022 Earnings Call Transcript
Via The Motley Fool
More Likely to 5x First: Novavax vs. Ocugen
Via The Motley Fool
Ocugen Appoints Quan A. Vu to Chief Financial Officer & Chief Business Officer
From Ocugen
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023
Via Benzinga
Why Catalyst Biosciences Shares Are Trading Higher By 105%; Here Are 20 Stocks Moving Premarket
Via Benzinga
1 Reason to Buy Ocugen in 2023 and 2 Reasons to Sell
Via The Motley Fool
Ocugen Provides Business Update with Fourth Quarter and Full Year 2022 Financial Results
From Ocugen
Via Globe NewsWire
Earnings Scheduled For February 28, 2023
Via Benzinga
Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1 Clinical Trial Evaluating OCU200 for the Treatment of Diabetic Macular Edema
From Ocugen
Via Globe NewsWire
Ocugen to Present at Retinal Vascular Disease Drug Development Summit
From Ocugen
Via Globe NewsWire
Ocugen to Host Conference Call on Tuesday, February 28 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2022 Financial Results
From Ocugen
Via Globe NewsWire
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
7 Heavily Shorted Penny Stocks for Your Short-Squeeze Watch List
Via InvestorPlace
Ocugen Appoints Quan A. Vu as Chief Business Officer
From Ocugen
Via Globe NewsWire
Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference
From Ocugen
Via Globe NewsWire
2 Struggling Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the Plague
Via The Motley Fool
Why GeneDx Holdings Shares Are Trading Lower By 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
3 of the Fastest-Growing Stocks on the Planet in 2023
Via The Motley Fool
3 Under-the-Radar Stocks With 590% to 772% Upside in 2023, According to Wall Street
Via The Motley Fool
7 ‘Loser’ Stocks to Short for Big Profits
Via InvestorPlace
Exclusive: Top 10 Most Searched Tickers On Benzinga Pro In 2022 — Where Do SPY, Tesla, Apple And AMC Rank?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.